<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021133</url>
  </required_header>
  <id_info>
    <org_study_id>H00022916</org_study_id>
    <secondary_id>P50CA244693</secondary_id>
    <nct_id>NCT05021133</nct_id>
  </id_info>
  <brief_title>Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)</brief_title>
  <official_title>Tele-Navigation of Lung Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meyers Primary Care Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adherence to annual follow up is critical to achieving mortality benefits and optimizing&#xD;
      cost-effectiveness of lung cancer screening (LCS). However, adherence to LCS follow-up in the&#xD;
      real world is suboptimal. Using telehealth, the investigators will co-create Tele-Navigation&#xD;
      of Lung Cancer Screening with patients and LCS stakeholders as an intervention to promote&#xD;
      adherence of follow-up LCS. The investigators will then implement the Tele-Navi LCS&#xD;
      intervention to a pilot sample of patients and evaluate its feasibility in the primary care&#xD;
      setting. The investigators will measure the number of patient participants who completed&#xD;
      Tele-Navi LCS and follow-up LCS within 180 days from Tele-Navi LCS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of Tele-Navi LCS</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants completed Tele-Navi LCS,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion of Follow-up LCS</measure>
    <time_frame>180 days</time_frame>
    <description>Number of participants who received a low-dose CT (LDCT) for LCS follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Tele-Navi LCS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Tele-Navi LCS</intervention_name>
    <description>Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS to access a patient portal and a video-call system.</description>
    <arm_group_label>Tele-Navi LCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has UMMHC PCP&#xD;
&#xD;
          -  Is eligible for LDCT for LCS follow-up&#xD;
&#xD;
          -  Has technology to complete study activities (e.g., video call visit)&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
          -  Is due for LDCT follow-up in the next 3-6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previous diagnosis of lung cancer&#xD;
&#xD;
          -  Has active cancer diagnosis&#xD;
&#xD;
          -  Is a nursing home or group care resident&#xD;
&#xD;
          -  Is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayuko Ito Fukunaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joann L Wagner, MSW</last_name>
    <phone>(508) 791-7392</phone>
    <email>Joann.Wagner@umassmed.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Mayuko Ito Fukunaga</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>cancer screening</keyword>
  <keyword>health informatics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified (by HIPAA standards) dataset may be made available to the public with PI approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

